Literature DB >> 2587617

Pharmacokinetics of galanthamine hydrobromide after single subcutaneous and oral dosage in humans.

D Mihailova1, I Yamboliev, Z Zhivkova, J Tencheva, V Jovovich.   

Abstract

Galanthamine hydrobromide (Nivalin, dose 10 mg) was given subcutaneously and orally to 8 volunteers. Galanthamine and its metabolites were quantified in plasma and urine by reversed-phase HPLC. An unusual two-stage absorption and biexponential drug decline were observed. Galanthamine plasma peaks (1.24 micrograms/ml after subcutaneous and 1.15 micrograms/ml after oral doses) were reached 2 h following administration, the t1/2(beta) values being 5.70 and 5.26 h, respectively. Minor epigalanthamine and galanthaminone plasma levels were detected. An almost complete urinary recovery of galanthamine and its metabolites was obtained within 72 h. The plasma AUC, Cmax, tmax and ka suggest that the subcutaneous and oral Nivalin formulations are bioequivalent.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2587617     DOI: 10.1159/000138571

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  8 in total

1.  Effective countermeasure against poisoning by organophosphorus insecticides and nerve agents.

Authors:  Edson X Albuquerque; Edna F R Pereira; Yasco Aracava; William P Fawcett; Maristela Oliveira; William R Randall; Tracey A Hamilton; Robert K Kan; James A Romano; Michael Adler
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-16       Impact factor: 11.205

2.  The N-butylcarbamate derivative of galantamine acts as an allosteric potentiating ligand on alpha7 nicotinic receptors in hippocampal neurons: clinical implications for treatment of Alzheimer's disease.

Authors:  Rodica V Popa; Edna F R Pereira; Cristiane Lopes; Alfred Maelicke; Edson X Albuquerque
Journal:  J Mol Neurosci       Date:  2006       Impact factor: 3.444

3.  Stereoselectivity of cholinesterase inhibition by galanthamine and tolerance in humans.

Authors:  T Thomsen; U Bickel; J P Fischer; H Kewitz
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 4.  Galantamine: a review of its use in Alzheimer's disease.

Authors:  L J Scott; K L Goa
Journal:  Drugs       Date:  2000-11       Impact factor: 9.546

Review 5.  Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors.

Authors:  Michael W Jann; Kara L Shirley; Gary W Small
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 6.  Galanthamine.

Authors:  B Fulton; P Benfield
Journal:  Drugs Aging       Date:  1996-07       Impact factor: 3.923

Review 7.  Clinical pharmacokinetics of galantamine.

Authors:  Martin R Farlow
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

8.  Symptomatic Treatment of Vascular Cognitive Impairment (STREAM-VCI): Protocol for a Cross-Over Trial.

Authors:  Jolien Fleur Leijenaar; Geert Jan Groeneveld; Wiesje Maria van der Flier; Philip Scheltens; Erica Surya Klaassen; Henry Chanoch Weinstein; Geert Jan Biessels; Frederik Barkhof; Niels Daniël Prins
Journal:  JMIR Res Protoc       Date:  2018-03-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.